Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

A Bayer testing of Compugen’s checkpoint protein in human trial boosted our expectations for Compugen’s resurrection

September 21, 2018 0

Compugen Again On Sept 10, 2018, we posted in The Week in Review #28 news we found …

About Portola’s appointment of a new president. Read Also: Why CRISPR lost $2.90 today

September 20, 2018 0

Portola Pharmaceuticals Appoints Scott Garland as President and Chief Executive Officer, Effective October 8, 2018. Portola (PTLA) appointed …

Exelixis: Health Canada approves Cabometyx in advanced renal cell carcinoma

September 20, 2018 0

Exelixis’ (EXEL) partner Ipsen Biopharmaceuticals Canada Inc. received approval of Cabometyx®(cabozantinib) tablets from Health Canada for adults with …

CRISPR Therapeutics’ new collaboration targeting Diabetes

September 19, 2018 0

CRISPR Gene Editing Beyond Bringing Cures to disease-causing genes, CRISPR gene editing technology can change the way diseases …

Viking Therapeutics: VK2809 scores impressive results in non-alcoholic fatty liver disease

September 18, 2018 2

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic …

Argenx’s product, Efgartigimod, demonstrates positive results in primary immune thrombocytopenia

September 17, 2018 0

Phase 2 clinical trial data of argenx’s (ARGX) product Efgartigimod (ARGX-113) in adult patients with primary immune …

AcelRx Pharmaceuticals: A small currently highlighted firm

September 14, 2018 0

Today, we see are observing an increased interest in AcelRx Pharmaceuticals (ACRX). The increased investors’ activity …

Gilead Sciences: In pursuit of cures for intractable diseases

September 13, 2018 0

Gilead Sciences (GILD) has news that we felt good about it for a company that saved …

CRISPR gene editing firms clear investors’ confusion

September 12, 2018 0

Playing buy and sell games with the CRISPR gene editing stocks is sometimes based on scientific …

Amgen and AstraZeneca have in hand a very much needed Asthma drug

September 11, 2018 0

In the Week in Review posted yesterday on our website that is experiencing several attempts on …

What is looking good in the aggressive portfolio

September 10, 2018 0

The Week in Review #29 PROHOST AGGRESSIVE PORTFOLIO - The aggressive portfolio hosts biotech firms with …

Gilead and Galapagos have good news for patients with severely active Ankylosing Spondylitis

September 7, 2018 0

Gilead Sciences’ (GILD) and Galapagos’ (GLPG) product filgotinib – a highly selective JAK1 inhibitor has met …

What happened to Sangamo yesterday?

September 6, 2018 0

The disease, mucopolysaccharidosis (MPS) type II, also known as the horrible Hunter syndrome is a killer …

Outperforming, favorite, and undervalued biotech firms

September 3, 2018 0

The Week in Review #28 The approval of revolutionary products created by biotech firms with solid …

RegenxBio has good news

August 30, 2018 0

We reiterate that undeniably outstanding news about gene therapy is taking time to penetrate investors’ ears. …

Ionis, the FDA and the exaggerated selloff of the firm’s stock

August 30, 2018 0

A complete response letter (CRL) sent by The Division of Metabolism and Endocrinology Products of the …

PTC Therapeutics now with a wealthier pipeline

August 28, 2018 0

Before we sell PTC Therapeutics (PTCT), after the stock had reached and surpassed our latest and …

About Portola

August 27, 2018 0

Portola (PTLA) has two important approved breakthrough products and an investigational product having promising results on …

When all the prophets are taken by surprise

August 24, 2018 0

When the Goal is Reaching into the Future, Pessimists Have No Place on the Ship The …

Why Celyad’s stock gained $2.30 today

August 23, 2018 0

Celyad (CYAD) is an immuno-oncology firm, which created CAR T CELL treatments for cancers, including solid …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

A Bayer testing of Compugen’s checkpoint protein in human trial boosted our expectations for Compugen’s resurrection

About Portola’s appointment of a new president. Read Also: Why CRISPR lost $2.90 today

Exelixis: Health Canada approves Cabometyx in advanced renal cell carcinoma

CRISPR Therapeutics’ new collaboration targeting Diabetes

Viking Therapeutics: VK2809 scores impressive results in non-alcoholic fatty liver disease

Argenx’s product, Efgartigimod, demonstrates positive results in primary immune thrombocytopenia

AcelRx Pharmaceuticals: A small currently highlighted firm

Gilead Sciences: In pursuit of cures for intractable diseases

CRISPR gene editing firms clear investors’ confusion

Amgen and AstraZeneca have in hand a very much needed Asthma drug

What is looking good in the aggressive portfolio

Gilead and Galapagos have good news for patients with severely active Ankylosing Spondylitis

What happened to Sangamo yesterday?

Outperforming, favorite, and undervalued biotech firms

RegenxBio has good news

Ionis, the FDA and the exaggerated selloff of the firm’s stock

PTC Therapeutics now with a wealthier pipeline

About Portola

When all the prophets are taken by surprise

Why Celyad’s stock gained $2.30 today